Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.

Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, Duijf PH, Vennin C, Raninga P, Nanayakkara D, Mittal D, Saunus JM, Lakhani SR, López JA, Spring KJ, Timpson P, Gabrielli B, Waddell N, Khanna KK.

EMBO Mol Med. 2018 Sep;10(9). pii: e8566. doi: 10.15252/emmm.201708566.

2.

Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo.

Stevenson AJ, Ager EI, Proctor MA, Škalamera D, Heaton A, Brown D, Gabrielli BG.

Sci Rep. 2018 Mar 23;8(1):5144. doi: 10.1038/s41598-018-22882-w.

3.

Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In Vivo.

Oo ZY, Stevenson AJ, Proctor M, Daignault SM, Walpole S, Lanagan C, Chen J, Škalamera D, Spoerri L, Ainger SA, Sturm RA, Haass NK, Gabrielli B.

Clin Cancer Res. 2018 Jun 15;24(12):2901-2912. doi: 10.1158/1078-0432.CCR-17-2701. Epub 2018 Mar 13.

PMID:
29535131
4.

Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.

Oncotarget. 2017 Dec 24;9(9):8206-8222. doi: 10.18632/oncotarget.23654. eCollection 2018 Feb 2.

5.

Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.

Clin Cancer Res. 2018 Mar 1;24(5):1090-1102. doi: 10.1158/1078-0432.CCR-16-2118. Epub 2017 Dec 1.

PMID:
29196297
6.

Keratinocyte Sonic Hedgehog Upregulation Drives the Development of Giant Congenital Nevi via Paracrine Endothelin-1 Secretion.

Chitsazan A, Ferguson B, Villani R, Handoko HY, Mukhopadhyay P, Gabrielli B, Mooi WJ, Soyer HP, Lambie D, Khosrotehrani K, Morahan G, Walker GJ.

J Invest Dermatol. 2018 Apr;138(4):893-902. doi: 10.1016/j.jid.2017.10.032. Epub 2017 Nov 11.

PMID:
29138054
7.

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells.

Levrier C, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Sadowski MC, Nelson CC.

Cell Cycle. 2018;17(5):652-668. doi: 10.1080/15384101.2017.1356512.

8.

Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors.

Martin D, Fallaha S, Proctor M, Stevenson A, Perrin L, McMillan N, Gabrielli B.

Mol Cancer Ther. 2017 Sep;16(9):1934-1941. doi: 10.1158/1535-7163.MCT-17-0159. Epub 2017 May 18.

9.

Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities.

Haass NK, Gabrielli B.

Exp Dermatol. 2017 Jul;26(7):649-655. doi: 10.1111/exd.13303. Epub 2017 Apr 20.

PMID:
28109167
10.

Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints.

D Arcy N, Gabrielli B.

Curr Med Chem. 2017;24(15):1504-1519. doi: 10.2174/0929867323666161205122613. Review.

PMID:
27919216
11.

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer.

Škalamera D, Dahmer-Heath M, Stevenson AJ, Pinto C, Shah ET, Daignault SM, Said NA, Davis M, Haass NK, Williams ED, Hollier BG, Thompson EW, Gabrielli B, Gonda TJ.

Oncotarget. 2016 Sep 20;7(38):61000-61020. doi: 10.18632/oncotarget.11314.

12.

Genome-Wide Overexpression Screen Identifies Genes Able to Bypass p16-Mediated Senescence in Melanoma.

Lee WJ, Škalamera D, Dahmer-Heath M, Shakhbazov K, Ranall MV, Fox C, Lambie D, Stevenson AJ, Yaswen P, Gonda TJ, Gabrielli B.

SLAS Discov. 2017 Mar;22(3):298-308. doi: 10.1177/1087057116679592. Epub 2016 Nov 23.

13.

6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.

Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.

Mol Cancer Ther. 2017 Jan;16(1):3-15. doi: 10.1158/1535-7163.MCT-16-0325. Epub 2016 Oct 19.

14.

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation.

Fox C, Lambie D, Wilmott JS, Pinder A, Pavey S, Lê Cao KA, Akalin T, Karaarslan IK, Ozdemir F, Scolyer RA, Yamada M, Soyer HP, Schaider H, Gabrielli B.

Pigment Cell Melanoma Res. 2016 Jul;29(4):444-52. doi: 10.1111/pcmr.12489.

PMID:
27166757
15.

A mutation in the Cdon gene potentiates congenital nevus development mediated by NRAS(Q61K).

Chitsazan A, Ferguson B, Ram R, Mukhopadhyay P, Handoko HY, Gabrielli B, Soyer PH, Morahan G, Walker GJ.

Pigment Cell Melanoma Res. 2016 Jul;29(4):459-64. doi: 10.1111/pcmr.12487.

PMID:
27155367
16.

In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis.

Vaidyanathan S, Cato K, Tang L, Pavey S, Haass NK, Gabrielli BG, Duijf PH.

Oncogene. 2016 Oct 13;35(41):5446-5455. doi: 10.1038/onc.2016.94. Epub 2016 Apr 11.

PMID:
27065322
17.

Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells.

Beaumont KA, Hill DS, Daignault SM, Lui GYL, Sharp DM, Gabrielli B, Weninger W, Haass NK.

J Invest Dermatol. 2016 Jul;136(7):1479-1489. doi: 10.1016/j.jid.2016.02.805. Epub 2016 Mar 10.

18.

Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer.

Harrington BS, He Y, Davies CM, Wallace SJ, Adams MN, Beaven EA, Roche DK, Kennedy C, Chetty NP, Crandon AJ, Flatley C, Oliveira NB, Shannon CM, deFazio A, Tinker AV, Gilks CB, Gabrielli B, Brennan DJ, Coward JI, Armes JE, Perrin LC, Hooper JD.

Br J Cancer. 2016 Feb 16;114(4):417-26. doi: 10.1038/bjc.2015.471. Epub 2016 Feb 4.

19.

A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma.

Spoerri L, Brooks K, Chia K, Grossman G, Ellis JJ, Dahmer-Heath M, Škalamera D, Pavey S, Burmeister B, Gabrielli B.

Pigment Cell Melanoma Res. 2016 May;29(3):329-39. doi: 10.1111/pcmr.12466. Epub 2016 Mar 17.

PMID:
26854966
20.

Self-Renewal and High Proliferative Colony Forming Capacity of Late-Outgrowth Endothelial Progenitors Is Regulated by Cyclin-Dependent Kinase Inhibitors Driven by Notch Signaling.

Patel J, Wong HY, Wang W, Alexis J, Shafiee A, Stevenson AJ, Gabrielli B, Fisk NM, Khosrotehrani K.

Stem Cells. 2016 Apr;34(4):902-12. doi: 10.1002/stem.2262. Epub 2016 Jan 6.

21.

A distinct expression profile separates Turkish and Australian melanocytic naevi.

Fox C, Schaider H, Akalin T, Turkmen M, Sturm R, Lambie D, Karaarslan IK, Soyer HP, Ozdemir F, Gabrielli B.

Histopathology. 2016 Jul;69(1):151-4. doi: 10.1111/his.12906. Epub 2016 Jan 21. No abstract available.

PMID:
26599517
22.

Aurora A Is Critical for Survival in HPV-Transformed Cervical Cancer.

Gabrielli B, Bokhari F, Ranall MV, Oo ZY, Stevenson AJ, Wang W, Murrell M, Shaikh M, Fallaha S, Clarke D, Kelly M, Sedelies K, Christensen M, McKee S, Leggatt G, Leo P, Skalamera D, Soyer HP, Gonda TJ, McMillan NA.

Mol Cancer Ther. 2015 Dec;14(12):2753-61. doi: 10.1158/1535-7163.MCT-15-0506. Epub 2015 Oct 29.

23.

Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.

Fraticelli P, De Vita S, Franzolini N, Svegliati S, Scott CA, Tonnini C, Spadoni T, Gabrielli B, Pomponio G, Moroncini G, Gabrielli A.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S160-7. Epub 2015 Sep 1.

PMID:
26339895
24.

JIP4 is a PLK1 binding protein that regulates p38MAPK activity in G2 phase.

Pinder A, Loo D, Harrington B, Oakes V, Hill MM, Gabrielli B.

Cell Signal. 2015 Nov;27(11):2296-303. doi: 10.1016/j.cellsig.2015.08.009. Epub 2015 Aug 17.

PMID:
26291670
25.

An observational cohort study of patients with newly diagnosed digital ulcer disease secondary to systemic sclerosis registered in the EUSTAR database.

Brand M, Hollaender R, Rosenberg D, Scott M, Hunsche E, Tyndall A, Denaro V, Carreira P, Varju C, Gabrielli B, Zingarelli S, Caramaschi P, Simic-Pasalic K, Müller-Ladner U, Vasile M, Mihai C, Rosato E, Vacca A, Zenone T, Mohamed WA, Ancuta C, Zampogna G, Rednic S, Jabaar N, Belloli L, Pozzi MR, Foti R, Walker UA; EUSTAR Co-Investigators.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S47-54. Epub 2015 Aug 5.

PMID:
26243652
26.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4545. doi: 10.1038/onc.2014.432. Epub 2015 Jan 26.

PMID:
25619837
27.

Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Irvine KM, Skoien R, Bokil NJ, Melino M, Thomas GP, Loo D, Gabrielli B, Hill MM, Sweet MJ, Clouston AD, Powell EE.

World J Gastroenterol. 2014 Dec 21;20(47):17851-62. doi: 10.3748/wjg.v20.i47.17851.

28.

Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.

Oakes V, Wang W, Harrington B, Lee WJ, Beamish H, Chia KM, Pinder A, Goto H, Inagaki M, Pavey S, Gabrielli B.

Cell Cycle. 2014;13(20):3302-11. doi: 10.4161/15384101.2014.949111.

29.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4448-59. doi: 10.1038/onc.2014.372. Epub 2014 Nov 24. Erratum in: Oncogene. 2015 Aug 20;34(34):4545.

30.

DCT protects human melanocytic cells from UVR and ROS damage and increases cell viability.

Ainger SA, Yong XL, Wong SS, Skalamera D, Gabrielli B, Leonard JH, Sturm RA.

Exp Dermatol. 2014 Dec;23(12):916-21. doi: 10.1111/exd.12574.

PMID:
25346513
31.

Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.

Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Moroncini G, Gabrielli A; Imatinib in Scleroderma Italian Study Group.

Arthritis Res Ther. 2014 Jul 8;16(4):R144. doi: 10.1186/ar4606.

32.

Decatenation checkpoint-defective melanomas are dependent on PI3K for survival.

Brooks K, Ranall M, Spoerri L, Stevenson A, Gunasingh G, Pavey S, Meunier F, Gonda TJ, Gabrielli B.

Pigment Cell Melanoma Res. 2014 Sep;27(5):813-21. doi: 10.1111/pcmr.12268. Epub 2014 Jun 23.

PMID:
24890688
33.

Rapid mapping of interactions between Human SNX-BAR proteins measured in vitro by AlphaScreen and single-molecule spectroscopy.

Sierecki E, Stevers LM, Giles N, Polinkovsky ME, Moustaqil M, Mureev S, Johnston WA, Dahmer-Heath M, Skalamera D, Gonda TJ, Gabrielli B, Collins BM, Alexandrov K, Gambin Y.

Mol Cell Proteomics. 2014 Sep;13(9):2233-45. doi: 10.1074/mcp.M113.037275. Epub 2014 May 27.

34.

Defective decatenation checkpoint function is a common feature of melanoma.

Brooks K, Chia KM, Spoerri L, Mukhopadhyay P, Wigan M, Stark M, Pavey S, Gabrielli B.

J Invest Dermatol. 2014 Jan;134(1):150-158. doi: 10.1038/jid.2013.264. Epub 2013 Jun 13.

35.

CDC25B overexpression stabilises centrin 2 and promotes the formation of excess centriolar foci.

Boutros R, Mondesert O, Lorenzo C, Astuti P, McArthur G, Chircop M, Ducommun B, Gabrielli B.

PLoS One. 2013 Jul 1;8(7):e67822. doi: 10.1371/journal.pone.0067822. Print 2013.

36.

DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma.

Pavey S, Spoerri L, Haass NK, Gabrielli B.

Pigment Cell Melanoma Res. 2013 Nov;26(6):805-16. doi: 10.1111/pcmr.12136. Epub 2013 Aug 5. Review.

PMID:
23837768
37.

Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients.

Sturm RA, Fox C, McClenahan P, Jagirdar K, Ibarrola-Villava M, Banan P, Abbott NC, Ribas G, Gabrielli B, Duffy DL, Peter Soyer H.

J Invest Dermatol. 2014 Jan;134(1):141-149. doi: 10.1038/jid.2013.272. Epub 2013 Jun 17.

38.

Oxidative stress and cell senescence combine to cause maximal renal tubular epithelial cell dysfunction and loss in an in vitro model of kidney disease.

Small DM, Bennett NC, Roy S, Gabrielli BG, Johnson DW, Gobe GC.

Nephron Exp Nephrol. 2012;122(3-4):123-30. doi: 10.1159/000350726. Epub 2013 Jun 1.

PMID:
23735887
39.

Truncated MEK1 is required for transient activation of MAPK signalling in G2 phase cells.

Pike T, Widberg C, Goodall A, Payne E, Giles N, Hancock J, Gabrielli B.

Cell Signal. 2013 Jun;25(6):1423-8. doi: 10.1016/j.cellsig.2013.03.014. Epub 2013 Mar 22.

PMID:
23524336
40.

Similar, not the same: diverse roles and regulation of cyclin Es.

Spoerri L, Gabrielli B.

Cell Cycle. 2013 Mar 1;12(5):715. doi: 10.4161/cc.23909. Epub 2013 Feb 19. No abstract available.

41.

Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer.

Škalamera D, Dahmer M, Purdon AS, Wilson BM, Ranall MV, Blumenthal A, Gabrielli B, Gonda TJ.

PLoS One. 2012;7(12):e51733. doi: 10.1371/journal.pone.0051733. Epub 2012 Dec 12.

42.

MicroRNA-182-5p targets a network of genes involved in DNA repair.

Krishnan K, Steptoe AL, Martin HC, Wani S, Nones K, Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Gabrielli B, Vlassov A, Cloonan N, Grimmond SM.

RNA. 2013 Feb;19(2):230-42. doi: 10.1261/rna.034926.112. Epub 2012 Dec 18.

43.

Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.

Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A.

Rheumatology (Oxford). 2013 Jan;52(1):143-54. doi: 10.1093/rheumatology/kes303. Epub 2012 Nov 22. Review.

PMID:
23175568
44.

Histone deacetylase inhibitors disrupt the mitotic spindle assembly checkpoint by targeting histone and nonhistone proteins.

Gabrielli B, Brown M.

Adv Cancer Res. 2012;116:1-37. doi: 10.1016/B978-0-12-394387-3.00001-X. Review.

PMID:
23088867
45.

Keeping replicative stress in Chk.

Brooks K, Gabrielli B.

Cell Cycle. 2012 Jun 1;11(11):2039-40. doi: 10.4161/cc.20425. Epub 2012 Jun 1. No abstract available.

PMID:
22580467
46.

A UVR-induced G2-phase checkpoint response to ssDNA gaps produced by replication fork bypass of unrepaired lesions is defective in melanoma.

Wigan M, Pinder A, Giles N, Pavey S, Burgess A, Wong S, Sturm RA, Gabrielli B.

J Invest Dermatol. 2012 Jun;132(6):1681-8. doi: 10.1038/jid.2012.41. Epub 2012 Mar 8.

47.

A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress.

Brooks K, Oakes V, Edwards B, Ranall M, Leo P, Pavey S, Pinder A, Beamish H, Mukhopadhyay P, Lambie D, Gabrielli B.

Oncogene. 2013 Feb 7;32(6):788-96. doi: 10.1038/onc.2012.72. Epub 2012 Mar 5.

PMID:
22391562
48.

Defective cell cycle checkpoints as targets for anti-cancer therapies.

Gabrielli B, Brooks K, Pavey S.

Front Pharmacol. 2012 Feb 2;3:9. doi: 10.3389/fphar.2012.00009. eCollection 2012.

49.

Histone deacetylase inhibitors in the generation of the anti-tumour immune response.

Leggatt GR, Gabrielli B.

Immunol Cell Biol. 2012 Jan;90(1):33-8. doi: 10.1038/icb.2011.94. Epub 2011 Nov 8. Review.

PMID:
22064708
50.

A management of blunt thoracic trauma in an emergency department observation unit: pre-post observational study.

Menditto VG, Gabrielli B, Marcosignori M, Screpante F, Pupita G, Polonara S, Salvi A, Raggetti GM, Pomponio G.

J Trauma Acute Care Surg. 2012 Jan;72(1):222-8. doi: 10.1097/TA.0b013e3182140cad.

PMID:
21926647

Supplemental Content

Loading ...
Support Center